Hezhen Chu
Hezhen Chu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chuanzhi Guo
School of Life Sciences, Jiangsu University, Zhenjiang 212013, China
1 shared publication - Haifeng Shi
School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu 212000, China
1 shared publication - Jie Gu
School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, 212013, China
1 shared publication Jun Ma
Department of Urology, Yixing Hospital of Traditional Chinese Medicine, Yixing, Jiangsu, 214200, China
1 shared publicationJunjie Liu
Department of Urology, Yixing Hospital of Traditional Chinese Medicine, Yixing, Jiangsu, 214200, China
1 shared publication- Wenchao Xie
Department of Urology, Affiliated Hospital of Jiangsu University-Yixing People’s Hospital, Yixing
1 shared publication
Latest Publications
- 11 March 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 393, 110948
New Ca2+ based anticancer nanomaterials trigger multiple cell death targeting Ca2+ homeostasis for cancer therapy
- 11 March 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 393, 110948
New Ca2+ based anticancer nanomaterials trigger multiple cell death targeting Ca2+ homeostasis for cancer therapy
- Open Access
- 1 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 5963-5971
Inhibiting stanniocalcin 2 reduces sunitinib resistance of Caki-1 renal cancer cells under hypoxia condition
Background: Our previous study has suggested that blocking stanniocalcin 2 (STC2) could reduce sunitinib resistance in clear cell renal cell carcinoma (ccRCC) under normoxia. The hypoxia is a particularly important environment for RCC occurrence and development, as well as sunitinib resistance. The authors proposed that STC2 also plays important roles in RCC sunitinib resistance under hypoxia conditions. Methods: The ccRCC Caki-1 cells were treated within the hypoxia conditions. Real-time quantitative PCR and Western blotting were applied to detect the STC2 expression in ccRCC Caki-1 cells. STC2-neutralizing antibodies, STC2 siRNA, and the recombinant human STC2 (rhSTC2) were used to identify targeting regulation on STC2 in modulating sunitinib resistance, proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion. In addition, autophagy flux and the lysosomal acidic environment were investigated by Western blotting and fluorescence staining, and the accumulation of sunitinib in cells was observed with the addition of STC2-neutralizing antibodies and autophagy modulators. Results: Under hypoxia conditions, sunitinib disrupted the lysosomal acidic environment and accumulated in Caki-1 cells. Hypoxia-induced the STC2 mRNA and protein levels in Caki-1 cells. STC2-neutralizing antibodies and STC2 siRNA effectively aggravated sunitinib-reduced cell viability and proliferation, which were reversed by rhSTC2. In addition, sunitinib promoted EMT, migration, and invasion, which were reduced by STC2-neutralizing antibodies. Conclusion: Inhibiting STC2 could reduce the sunitinib resistance of ccRCC cells under hypoxia conditions.
- 1 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 5963-5971
Open AccessInhibiting stanniocalcin 2 reduces sunitinib resistance of Caki-1 renal cancer cells under hypoxia condition
Background: Our previous study has suggested that blocking stanniocalcin 2 (STC2) could reduce sunitinib resistance in clear cell renal cell carcinoma (ccRCC) under normoxia. The hypoxia is a particularly important environment for RCC occurrence and development, as well as sunitinib resistance. The authors proposed that STC2 also plays important roles in RCC sunitinib resistance under hypoxia conditions. Methods: The ccRCC Caki-1 cells were treated within the hypoxia conditions. Real-time quantitative PCR and Western blotting were applied to detect the STC2 expression in ccRCC Caki-1 cells. STC2-neutralizing antibodies, STC2 siRNA, and the recombinant human STC2 (rhSTC2) were used to identify targeting regulation on STC2 in modulating sunitinib resistance, proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion. In addition, autophagy flux and the lysosomal acidic environment were investigated by Western blotting and fluorescence staining, and the accumulation of sunitinib in cells was observed with the addition of STC2-neutralizing antibodies and autophagy modulators. Results: Under hypoxia conditions, sunitinib disrupted the lysosomal acidic environment and accumulated in Caki-1 cells. Hypoxia-induced the STC2 mRNA and protein levels in Caki-1 cells. STC2-neutralizing antibodies and STC2 siRNA effectively aggravated sunitinib-reduced cell viability and proliferation, which were reversed by rhSTC2. In addition, sunitinib promoted EMT, migration, and invasion, which were reduced by STC2-neutralizing antibodies. Conclusion: Inhibiting STC2 could reduce the sunitinib resistance of ccRCC cells under hypoxia conditions.